APEA- Endocrine Pharm | Questions with 100% Verified
Answers | Latest Update 2026/2027
Question: Aspart (NovoLog) should be administered: 10 minutes prior to a meal. 30 minutes prior to a meal. 30
minutes after a meal. just before sleep.
Answer: 10 minutes prior to a meal
Question: Maximum plasma concentrations of glucagon, after intramuscular injection, are observed in
approximately: 5 minutes. 15 minutes. 30 minutes. 45 minutes.
Answer: 15 minutes. The maximum plasma concentration of glucagon, after intramuscular administration to a
patient with severe hypoglycemia, are obtained in approximately 13 minutes
Question: Patients who are receiving radioiodine therapy for hyperthyroidism should be advised to: avoid
contact with young children for several days. avoid becoming pregnant during treatment and for 12 months
after treatment. expect hair loss over the next 3 months. monitor for laryngeal damage.
Answer: avoid contact with young children for several days. Patients who receive radioiodine have the
potential to expose their home and household contacts via saliva and urine due to radiation emitting from their
body. Patients must take radiation precautions for several days after treatment, avoiding contact with young
children and pregnant women.
Question: Because of the mechanism of action, patients should be instructed to administer exenatide (Byetta):
daily at bedtime. immediately following the largest meal of the day. twice daily, within 1 hour prior to morning
and evening meals. at least 12 hours apart, regardless of meals.
Answer: twice daily, within 1 hour prior to morning and evening meals. Patients should be instructed to
administer exenatide (Byetta) within 60 minutes prior to the morning and evening meal (or prior to the 2 main
meals of the day). Injections should be administered approximately =6 hours apart
Question: When patients administer regular insulin (Humulin R U-500), they should be taught: 5 units of
Humulin R U-500 is equal to 10 units on a U-100 insulin syringe. 10 units of Humulin R U-500 is equal to 5 units
on a U-100 insulin syringe. 10 units of Humulin R U-500 is equal to 10 units on a U-500 insulin syringe. it should
only be used in an insulin pump.
Answer: 10 units of Humulin R U-500 is equal to 10 units on a U-500 insulin syringe. For safety, ONLY the U-500
syringe should be used. It is not recommended for use in insulin pumps due to possibility of precipitation.
Question: The combination of metformin (Glucophage) and glyburide (Diabeta) for the treatment of Type 2
diabetes is: moderately efficacious with low risk of hypoglycemia. moderately efficacious with high risk of
hypoglycemia. highly efficacious with moderate risk of hypoglycemia. highly efficacious with low risk of
hypoglycemia.
Answer: highly efficacious with moderate risk of hypoglycemia. Because the effect of these 2 medications in
combination is additive, together they can potentially decrease A1C 2-4%. This is considered highly efficacious.
Question: Insulin glargine (Lantus) is NOT indicated in the treatment of: adults with Type 1 diabetes mellitus.
adults with Type 2 diabetes mellitus. pediatric patients with Type 1 diabetes mellitus. pediatric patients with
Type 2 diabetes mellitus.
Answer: pediatric patients with Type 2 diabetes mellitus. The FDA has not approved Lantus for use in children
with Type 2 diabetes.
Question: Insulin detemir (Levemir): has a longer duration of action than insulin glargine (Lantus). may be used
in insulin pumps. may be administered once or twice daily. is indicated as monotherapy for patients with Type
1 diabetes mellitus.
Answer: may be administered once or twice daily.
, Question: A 48-year-old patient is started on metformin (Glucophage) for Type 2 diabetes (T2DM). The
maximum expected hemoglobin A1C reduction after initiation of this medication is: 0.5%. 1%. 2%. 3%.
Answer: 2%
Question: Due to the mechanism of action of meglitinides used in the treatment of Type 2 diabetes, they
should be administered: at meal time. at bedtime. 2 hours after a meal. 2 hours before the largest meal of the
day.
Answer: at meal time. When taken on an empty stomach they have a 56% bioavailability when absorbed from
the gastrointestinal tract. Bioavailability is reduced when taken with food; the maximum concentration
decreases by 20%, therefore reducing the risk of hypoglycemia. They should be administered within 30
minutes of a meal or at mealtime 2-4 times daily.
Question: Which of the following side effects may be caused by methimazole (Tapazole)? Osteoporosis Anxiety
Hypothyroidism Supraventricular tachycardia
Answer: Hypothyroidism Methimazole (Tapazole) can cause hypothyroidism, necessitating routine monitoring
of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Other serious adverse
reactions to methimazole (Tapazole) may include bone marrow suppression, hepatotoxicity, exfoliative
dermatitis, unexplained fever, lupus-like syndrome and vasculitis.
Question: Signs and symptoms of hypoglycemia may be blunted by: beta-blockers. calcium-channel blockers.
diuretics. thyroid hormones.
Answer: beta-blockers. Classically, hypoglycemia is evidenced by shakiness or jitteriness in a patient who is
experiencing hypoglycemia. Beta blockers mask these signs by inhibiting these symptoms. Hence, diabetics
who take beta blockers may not experience these signs of hypoglycemia and should be taught to watch for
diaphoresis
Question: Sulfonylureas such as glyburide (Micronase) are extensively metabolized: in the small intestine. by
the renal nephrons. in the liver. by beta cells in the pancreas.
Answer: in the liver.
Question: A patient who is started on a glucagon-like peptide (GLP-1), such as Victoza, should be informed that
this class of medications may: increase satiety. cause hypoglycemia. cause weight gain. are inexpensive.
Answer: increase satiety.
Question: The most common serious side effect associated with glimepiride (Amaryl) is: asthenia. diarrhea.
hypoglycemia. metallic taste.
Answer: hypoglycemia.
Question: A patient is started on a sulfonylurea (i.e., glyburide). The nurse practitioner informs the patient that
sulfonylureas are likely to: cause weight loss. reduce microvascular events. delay gastric emptying. reduce the
risk of hypoglycemic events.
Answer: reduce microvascular events. The advantages of sulfonylureas such as glyburide (DiaBeta) are that
they are low cost, have a long use history, and cause a reduction in micro/macrovascular events.
Disadvantages are they produce hypoglycemia and cause weight gain.
Question: Levothyroxine (Synthroid) is indicated in the treatment of: hyperthyroidism. hypothyroidism.
thyrotoxicosis. weight reduction.
Answer: hypothyroidism.
Answers | Latest Update 2026/2027
Question: Aspart (NovoLog) should be administered: 10 minutes prior to a meal. 30 minutes prior to a meal. 30
minutes after a meal. just before sleep.
Answer: 10 minutes prior to a meal
Question: Maximum plasma concentrations of glucagon, after intramuscular injection, are observed in
approximately: 5 minutes. 15 minutes. 30 minutes. 45 minutes.
Answer: 15 minutes. The maximum plasma concentration of glucagon, after intramuscular administration to a
patient with severe hypoglycemia, are obtained in approximately 13 minutes
Question: Patients who are receiving radioiodine therapy for hyperthyroidism should be advised to: avoid
contact with young children for several days. avoid becoming pregnant during treatment and for 12 months
after treatment. expect hair loss over the next 3 months. monitor for laryngeal damage.
Answer: avoid contact with young children for several days. Patients who receive radioiodine have the
potential to expose their home and household contacts via saliva and urine due to radiation emitting from their
body. Patients must take radiation precautions for several days after treatment, avoiding contact with young
children and pregnant women.
Question: Because of the mechanism of action, patients should be instructed to administer exenatide (Byetta):
daily at bedtime. immediately following the largest meal of the day. twice daily, within 1 hour prior to morning
and evening meals. at least 12 hours apart, regardless of meals.
Answer: twice daily, within 1 hour prior to morning and evening meals. Patients should be instructed to
administer exenatide (Byetta) within 60 minutes prior to the morning and evening meal (or prior to the 2 main
meals of the day). Injections should be administered approximately =6 hours apart
Question: When patients administer regular insulin (Humulin R U-500), they should be taught: 5 units of
Humulin R U-500 is equal to 10 units on a U-100 insulin syringe. 10 units of Humulin R U-500 is equal to 5 units
on a U-100 insulin syringe. 10 units of Humulin R U-500 is equal to 10 units on a U-500 insulin syringe. it should
only be used in an insulin pump.
Answer: 10 units of Humulin R U-500 is equal to 10 units on a U-500 insulin syringe. For safety, ONLY the U-500
syringe should be used. It is not recommended for use in insulin pumps due to possibility of precipitation.
Question: The combination of metformin (Glucophage) and glyburide (Diabeta) for the treatment of Type 2
diabetes is: moderately efficacious with low risk of hypoglycemia. moderately efficacious with high risk of
hypoglycemia. highly efficacious with moderate risk of hypoglycemia. highly efficacious with low risk of
hypoglycemia.
Answer: highly efficacious with moderate risk of hypoglycemia. Because the effect of these 2 medications in
combination is additive, together they can potentially decrease A1C 2-4%. This is considered highly efficacious.
Question: Insulin glargine (Lantus) is NOT indicated in the treatment of: adults with Type 1 diabetes mellitus.
adults with Type 2 diabetes mellitus. pediatric patients with Type 1 diabetes mellitus. pediatric patients with
Type 2 diabetes mellitus.
Answer: pediatric patients with Type 2 diabetes mellitus. The FDA has not approved Lantus for use in children
with Type 2 diabetes.
Question: Insulin detemir (Levemir): has a longer duration of action than insulin glargine (Lantus). may be used
in insulin pumps. may be administered once or twice daily. is indicated as monotherapy for patients with Type
1 diabetes mellitus.
Answer: may be administered once or twice daily.
, Question: A 48-year-old patient is started on metformin (Glucophage) for Type 2 diabetes (T2DM). The
maximum expected hemoglobin A1C reduction after initiation of this medication is: 0.5%. 1%. 2%. 3%.
Answer: 2%
Question: Due to the mechanism of action of meglitinides used in the treatment of Type 2 diabetes, they
should be administered: at meal time. at bedtime. 2 hours after a meal. 2 hours before the largest meal of the
day.
Answer: at meal time. When taken on an empty stomach they have a 56% bioavailability when absorbed from
the gastrointestinal tract. Bioavailability is reduced when taken with food; the maximum concentration
decreases by 20%, therefore reducing the risk of hypoglycemia. They should be administered within 30
minutes of a meal or at mealtime 2-4 times daily.
Question: Which of the following side effects may be caused by methimazole (Tapazole)? Osteoporosis Anxiety
Hypothyroidism Supraventricular tachycardia
Answer: Hypothyroidism Methimazole (Tapazole) can cause hypothyroidism, necessitating routine monitoring
of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Other serious adverse
reactions to methimazole (Tapazole) may include bone marrow suppression, hepatotoxicity, exfoliative
dermatitis, unexplained fever, lupus-like syndrome and vasculitis.
Question: Signs and symptoms of hypoglycemia may be blunted by: beta-blockers. calcium-channel blockers.
diuretics. thyroid hormones.
Answer: beta-blockers. Classically, hypoglycemia is evidenced by shakiness or jitteriness in a patient who is
experiencing hypoglycemia. Beta blockers mask these signs by inhibiting these symptoms. Hence, diabetics
who take beta blockers may not experience these signs of hypoglycemia and should be taught to watch for
diaphoresis
Question: Sulfonylureas such as glyburide (Micronase) are extensively metabolized: in the small intestine. by
the renal nephrons. in the liver. by beta cells in the pancreas.
Answer: in the liver.
Question: A patient who is started on a glucagon-like peptide (GLP-1), such as Victoza, should be informed that
this class of medications may: increase satiety. cause hypoglycemia. cause weight gain. are inexpensive.
Answer: increase satiety.
Question: The most common serious side effect associated with glimepiride (Amaryl) is: asthenia. diarrhea.
hypoglycemia. metallic taste.
Answer: hypoglycemia.
Question: A patient is started on a sulfonylurea (i.e., glyburide). The nurse practitioner informs the patient that
sulfonylureas are likely to: cause weight loss. reduce microvascular events. delay gastric emptying. reduce the
risk of hypoglycemic events.
Answer: reduce microvascular events. The advantages of sulfonylureas such as glyburide (DiaBeta) are that
they are low cost, have a long use history, and cause a reduction in micro/macrovascular events.
Disadvantages are they produce hypoglycemia and cause weight gain.
Question: Levothyroxine (Synthroid) is indicated in the treatment of: hyperthyroidism. hypothyroidism.
thyrotoxicosis. weight reduction.
Answer: hypothyroidism.
